10:33 PM EDT, 09/20/2022 (MT Newswires) -- KeyMed Biosciences' (HKG:2162) swung to a profit attributable to owners of 5.4 million yuan ($766,958) for the six months ended June 30 from a loss of 3.63 billion yuan in the year earlier, according to a filing on Tuesday.
Earnings per share in the same half-year period came to 0.0208 yuan, compared with the loss per share of 54.08 yuan in the year prior.
The biotechnology company's revenue amounted to 100 million yuan, while gross profit came to 97.5 million yuan.
KeyMed's board did not propose any interim dividend for the first six months of 2022.
Shares slipped 3% in recent trade.